Your session is about to expire
← Back to Search
Unknown
AMX0035 for ALS (Phoenix Trial)
Phase 3
Waitlist Available
Research Sponsored by Amylyx Pharmaceuticals Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Time since onset of first symptom of ALS should be <24 months prior to randomization
Diagnosis of ALS (definite or clinically probable)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights
Phoenix Trial Summary
This trial is testing a new drug to see if it is safe and effective for treating ALS.
Who is the study for?
This trial is for adults diagnosed with ALS within the last 2 years who can consent and follow study procedures. They must use birth control during the study and not plan to conceive. Excluded are pregnant or breastfeeding women, those with severe medical conditions, on salt restriction, enrolled in other trials, using prohibited meds, or have specific health issues like low lung capacity or poor kidney function.Check my eligibility
What is being tested?
The Phoenix Trial is testing AMX0035 against a placebo to see if it's safe and effective for treating ALS. This Phase III trial randomly assigns participants to either receive AMX0035 or a placebo without them knowing which one they're getting (double-blind).See study design
What are the potential side effects?
While specific side effects of AMX0035 aren't listed here, common clinical trial risks may include allergic reactions to components of the treatment, gastrointestinal issues like nausea or diarrhea, fatigue, headaches, and potential liver enzyme elevations.
Phoenix Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My first ALS symptoms appeared less than 2 years ago.
Select...
I have been diagnosed with ALS.
Phoenix Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Slope Change And Survival
Number of Participants With Adverse Events
Number of Participants in Each Group Able to Remain on Study Drug Until Planned Discontinuation
Secondary outcome measures
Assess Long-Term Survival
Decline in King's and MiToS Stages
Participant Health Status
+3 moreSide effects data
From 2019 Phase 2 trial • 137 Patients • NCT0312751428%
Fall
21%
Diarrhoea
20%
Muscular weakness
18%
Nausea
15%
Headache
13%
Constipation
11%
Salivary hypersecretion
11%
Viral Upper Respiratory Tract Infection
10%
Dizziness
10%
Dyspnoea
8%
Abdominal pain
8%
Decreased appetite
8%
Fatigue
7%
Laceration
6%
Back pain
6%
Abdominal discomfort
6%
Muscle spasms
6%
Arthralgia
6%
Musculoskeletal pain
6%
Contusion
6%
Urinary Tract Infection
6%
Cough
6%
Weight decreased
6%
Asthenia
6%
Rash
4%
Aspartate aminotransferase increased
4%
Musculoskeletal chest pain
4%
Abdominal pain upper
4%
Upper Respiratory Tract Infection
4%
Alanine aminotransferase increased
3%
Dysphagia
3%
Dry mouth
3%
Insomnia
2%
Respiratory failure
2%
Neck pain
2%
Oedema peripheral
1%
Pneumoperitoneum
1%
Skull fracture
1%
Bacteraemia
1%
Cellulitis
1%
Pneumonia
1%
Diverticulitis
1%
Nephrolithiasis
1%
Respiratory arrest
1%
Vision blurred
1%
Subdural haematoma
1%
Stoma site haemorrhage
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
AMX0035
Phoenix Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: AMX0035Experimental Treatment1 Intervention
Placebo administered by mouth or via feeding tube for 48 weeks: once daily for first 3 weeks and then twice daily for remainder of study if participant tolerating
Group II: PlaceboPlacebo Group1 Intervention
Placebo administered by mouth or via feeding tube for 48 weeks: once daily for first 3 weeks and then twice daily for remainder of study if participant tolerating
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AMX0035
2018
Completed Phase 3
~360
Find a Location
Who is running the clinical trial?
Amylyx Pharmaceuticals Inc.Lead Sponsor
9 Previous Clinical Trials
1,581 Total Patients Enrolled
5 Trials studying Amyotrophic Lateral Sclerosis
860 Patients Enrolled for Amyotrophic Lateral Sclerosis
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I can and will follow all trial procedures and visit requirements.I haven't taken PB or taurursodiol in the last 30 days.My kidney function is low, with an eGFR under 60.You have a history of being allergic to phenyl butyrate or bile salts.I am on a strict low-salt diet for health reasons.My first ALS symptoms appeared less than 2 years ago.I have been diagnosed with ALS.I have not taken any prohibited medications in the last 30 days.I have a tracheostomy or use a ventilator to help me breathe.I can understand and agree to the study's details.I agree to use contraception during the study and for 3 months after.I have severe heart failure.I do not have any mental health or substance issues that would prevent me from understanding this study.I have been on a stable dose of riluzole and/or edaravone for the required time.I am 18 years old or older.I do not have severe liver or bile duct problems.I have had cellular or gene therapies for ALS.Your slow vital capacity (SVC) is less than 55%.You have a device called a Diaphragm Pacing System (DPS) implanted in your body.My liver tests are more than 5 times the normal limit.
Research Study Groups:
This trial has the following groups:- Group 1: AMX0035
- Group 2: Placebo
Awards:
This trial has 1 awards, including:- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How many people are total participating in this test?
"600 participants that meet the necessary requirements are needed for this study to happen. The sponsor, Amylyx Pharmaceuticals Inc., plans to host the trial at Providence St. Luke's Rehabilitation Medical Center in Spokane, Washington and University of Wisconsin-Madison in Madison, Wisconsin among other locations."
Answered by AI
What is the purpose of this clinical trial?
"According to the clinical trial sponsor, Amylyx Pharmaceuticals Inc., the primary objective of this study is to measure theAmyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Slope Change And Survival over a 48 week period. Additionally, this study will also be secondary outcomes including Long-Term Survival and Rate of Decline in Slow Vital Capacity (SVC). Quality of Life (QOL) for participants will also be measured using the 40-item Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40) patient-reported outcome (PRO)."
Answered by AI
Are patients being recruited for this research project at the moment?
"The trial, which was first advertised on clinicaltrials.gov on October 28th, 2021 is still recruiting participants according to the most recent update from October 5th, 2022."
Answered by AI
Who else is applying?
What state do they live in?
California
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger